论文部分内容阅读
目的观察孟鲁司特联合酮替芬对哮喘患者血清转化生长因子-β_1(TGF-β_1)、单核细胞趋化蛋白-1(MCP-1)、基质细胞衍生因子-1(SDF-1)水平的影响。方法 2014年10月—2015年10月南京医科大学附属无锡第二人民医院呼吸科收治哮喘患者128例,随机数字表法分为观察组及对照组各64例,2组患者均给予对症治疗,对照组同时给予孟鲁司特口服,观察组给予孟鲁司特联合酮替芬口服,治疗时间为3个月。观察2组患者治疗效果及治疗前后血清TGF-β_1、MCP-1、SDF-1水平的变化。结果观察组总有效率为96.9%,高于对照组的84.4%(P<0.05);治疗后,观察组哮喘控制测试表(ACT)评分为(24.25±3.98)分,显著高于对照组的(20.12±4.02)分(P<0.05);观察组第一秒呼气容积(FEV_1)和呼气峰值流速(PEF)分别为(80.25±4.25)%、(7.25±0.69)L/min,高于对照组的(75.02±3.96)%、(5.82±0.70)L/min(P<0.05);血清TGF-β_1、MCP-1、SDF-1水平分别为(42.2±6.0)ng/ml、(48.6±4.0)pg/ml、(252.4±32.2)ng/L,低于对照组的(48.9±5.2)ng/ml、(59.0±4.2)pg/ml、(425.3±40.6)ng/L,差异均有统计学意义(P<0.05)。结论孟鲁司特联合酮替芬能有效降低哮喘患者血清TGF-β_1、MCP-1、SDF-1水平,改善患者临床症状及肺功能,提高患者治疗效果。
Objective To observe the effects of montelukast combined with ketotifen on serum levels of TGF-β_1, MCP-1, SDF-1, Horizontal impact. Methods From October 2014 to October 2015, 128 cases of asthma were admitted to Respiratory Department of Wuxi Second People’s Hospital Affiliated to Nanjing Medical University. Random number table was divided into observation group (64 cases) and control group (64 cases). Patients in both groups were given symptomatic treatment, The control group was given montelukast orally, and the observation group was given montelukast combined with ketotifen for 3 months. The therapeutic effects and the changes of serum TGF-β 1, MCP-1 and SDF-1 levels before and after treatment were observed in two groups. Results The total effective rate in the observation group was 96.9%, higher than that in the control group (84.4%, P <0.05). After the treatment, the asthma control test (ACT) score in the observation group was (24.25 ± 3.98) points significantly higher than that in the control group (20.12 ± 4.02) points (P <0.05). The FEV 1 and PEF of observation group were (80.25 ± 4.25)%, (7.25 ± 0.69) L / min and (75.02 ± 3.96)% and (5.82 ± 0.70) L / min in the control group (P <0.05). The levels of serum TGF-β_1, MCP-1 and SDF-1 in the control group were 42.2 ± 6.0ng / 48.6 ± 4.0 pg / ml and 252.4 ± 32.2 ng / L, respectively, lower than that of the control group (48.9 ± 5.2) ng / ml, (59.0 ± 4.2) pg / ml and (425.3 ± 40.6) All were statistically significant (P <0.05). Conclusion Montelukast combined with ketotifen can effectively reduce the levels of serum TGF-β 1, MCP-1 and SDF-1 in asthmatic patients, improve the clinical symptoms and pulmonary function, and improve the therapeutic effect of the patients.